SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense volatility and speculative interest following its recent market debut, with the community actively debating whether it is a legitimate vehicle for private equity exposure or a highly overvalued pump-and-dump scheme. Investors are fixated on the fund's heavy concentration in high-profile pre-IPO tech firms like Anthropic and SpaceX, while many remain frustrated by a six-month lock-up period that limits liquidity for early participants.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox shares are experiencing significant volatility driven by the full notice to proceed on a massive $2.4 billion contract to build natural gas-fired power generation for AI data centers. Investors are actively debating the company's valuation, institutional backing, and the long-term impact of this infrastructure expansion as the market monitors the firm's transition into a key player for AI energy requirements.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant downward pressure and intense community debate as investors grapple with a sharp post-earnings sell-off that has defied positive analyst sentiment. Shareholders are actively questioning whether the volatility is driven by broader market instability and geopolitical tensions, or if it reflects deeper concerns over potential management alignment with a low-cost acquisition strategy.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is facing significant downward pressure and intense community debate surrounding regulatory risks, Medicare reimbursement uncertainty, and potential balance sheet strain. While some investors see a long-term value opportunity at current levels, others are expressing concern over the company's technical weakness and its ability to navigate a challenging macroeconomic and political landscape.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is at the center of investor focus following reports that it is in merger discussions with Spanish beauty group Puig. While the market is reacting to potential dilution risks and broader concerns over debt, the community is actively debating the deal's strategic viability versus its potential downside, with some seeing a long-term turnaround opportunity.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is seeing significant volatility as investors react to a major new volume order for 800G transceivers from a hyperscale customer, fueling excitement about the company's role in AI infrastructure. While the community is actively debating the stock's long-term growth potential and recent share offerings, momentum traders are focused on the intense volume and price swings following the news.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE meme coin is generating significant buzz as traders debate whether it could replicate the explosive momentum seen in similar speculative crypto assets. While some investors focus on signs of accumulation and relative price stability, others remain skeptical, warning of the risks inherent in such volatile market activity.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is currently trending due to its aggressive global expansion, including commercial robotaxi operations with Uber in the Middle East and new autonomous vehicle permits in Europe and Singapore. The community is actively debating the company's long-term valuation compared to regional peers and Waymo, as investors look for clarity on 2026 growth targets and the impact of recent institutional accumulation.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant volatility and heightened trading volume as investors position themselves ahead of the company's earnings report, with the community actively debating whether the stock's future revenue guidance and potential NASA contract awards will trigger a major breakout. Market participants are split between bullish enthusiasm over the company's backlog and long-term space infrastructure growth, and skeptical short-sellers concerned about valuation and execution risks.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is gaining significant traction on Solana as the community highlights its unique lock mechanisms and long-term holding culture. Investors are actively discussing the project's development milestones and its resilience, fueling widespread speculation about future growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Atomera’s stock offering is at a discount of 40% when compared to the closing price on Friday.</li><li>The company stated that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.</li><li>Atomera added that the stock offering is expected to close on or about Feb. 24, 2026.</li></ul>Atomera Inc. (ATOM) stock declined nearly 13% in Monday’s opening trade after the company announced the pricing of a new stock offering.Atomera announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share. This is at a discount of 40% from the stock’s closing price on Friday.<h2 class="st-heading-2">What Will Atomera Use The Funds For?</h2>Atomera stated in its announcement that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.The company added that the stock offering is expected to close on or about Feb. 24, 2026.Atomera reported its fourth-quarter (Q4) results earlier this month, posting a loss of $0.14 per share, in line with Wall Street expectations. The company reported revenue of $0.05 million, while the consensus estimate was $0.1 million, according to Stocktwits data.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ATOM">Atomera</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.Despite Atomera’s share price decline, one bullish user said it's a buying opportunity.<stembedurl>https://stocktwits.com/BioRocket/message/645608846</stembedurl>Another user stated they’re surprised by Atomera’s stock offering, noting that the company didn't need cash.<stembedurl>https://stocktwits.com/DinoMcnuggets/message/645607759</stembedurl><a href="https://stocktwits.com/symbol/ATOM">ATOM stock</a> is up 217% year-to-date and 9% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palo-alto-networks-removed-from-wedbush-best-ideas-list/cZRtp2lR4ya">Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Atomera Incorporated logo is seen displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Equity

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.</li><li>The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index at week 12.</li><li>Evommune said EVO301 showed a favorable safety profile with no serious adverse events reported.</li></ul>Evommune Inc. (EVMN) shares nearly doubled in value in Tuesday’s pre-market trade before paring some of the gains to hover 50% higher in the opening trade after the company reported positive results from its atopic dermatitis trial.Evommune stated that its atopic dermatitis treatment, EVO301, met its primary endpoint at week 12 during the&nbsp;mid-stage trial. The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/EVMN">Evommune</a> trended in the ‘neutral’ territory at the time of writing. The EVMN stock was among the top five trending tickers on the platform.<h2 class="st-heading-2">Evommune Details Results Of The Trial</h2>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.“These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes,” said Evommune President and CEO, Luis Peña.The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at week 12.Evommune said EVO301 showed a favorable safety profile, with no serious adverse events reported and no treatment-related discontinuations due to adverse events.Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, stated that EVO301’s ability to target the interleukin-18 (IL-18) mechanism and demonstrate clinically relevant activity could present patients with “real benefits.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user stated that there has been “only good news” with the Evommune stock so far.<stembedurl>https://stocktwits.com/swingingg/message/644564885</stembedurl>Another user stated that the IL-18, a known inflammatory pathway which plays a key role in various immune processes, is “working great” for dermatitis.<stembedurl>https://stocktwits.com/JanetBSmellin/message/644548490</stembedurl><a href="https://stocktwits.com/symbol/EVMN">EVMN stock</a> is up 45% year-to-date and 44% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/michael-saylor-bitcoin-volatility-bug-as-well-as-feature/cZbUI8AR4Yx">Michael Saylor Calls Bitcoin Volatility Both A Bug And A Feature, Touts It As ‘Digital Capital’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?

The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.

<ul class="summary-bullets"><li>In Kentucky, TeraWulf has acquired a former industrial site in Hawesville, which has approximately 480 MW of existing power availability.</li><li>In Maryland, where TeraWulf is headquartered, the company has acquired the Morgantown Generating Station.</li><li>This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually.</li></ul>Shares of TeraWulf (<a href="https://stocktwits.com/symbol/WULF">WULF</a>) surged more than 10% during extended hours of trading on Monday after the company announced that it is expanding its digital and power infrastructure portfolio.&nbsp;The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.<h2 class="st-heading-2">Details</h2>TeraWulf said these acquisitions added about 1.5 gigawatts (GW) of capacity to its portfolio and advanced the company’s strategy of developing energy-advantaged locations with near-term power availability, long-term scalability, and the ability to support customer demand and broader grid needs.In Kentucky, TeraWulf has acquired a former industrial site in Hawesville. The site includes more than 250 buildable acres for compute capacity and offers immediate access to robust power infrastructure, the statement said.&nbsp;The Hawesville site has approximately 480 megawatts (MW) of existing power availability, with the potential to further expand over time. Development is expected to occur in phases, allowing TeraWulf to scale efficiently alongside customer demand.In Maryland, where TeraWulf is headquartered, it has acquired the Morgantown Generating Station. The acquisition establishes TeraWulf’s presence in the Pennsylvania-New Jersey-Maryland (PJM) market and reinforces the company’s strategy of reinvesting in existing energy assets to support grid reliability and long-term economic activity.<h2 class="st-heading-2">Portfolio Expansion</h2>With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.“These acquisitions reflect our strategy of reinvesting in existing energy infrastructure to support grid reliability, long-term economic activity, and responsible growth,” said Paul Prager, Chairman and Chief Executive Officer of TeraWulf.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WULF trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user said that “2 additional site announcement today DOUBLES the AI/HPC capacity”.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/643740254</stembedurl>Shares in the company have jumped more than 200% over the past 12 months.&nbsp;&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Why Is TeraWulf Stock Rallying More Than 10% After Hours?

With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites.

<ul class="summary-bullets"><li>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva.</li><li>Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.</li><li>Last month, Immunitybio said that it recently met with the U.S. FDA to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.</li></ul>Immunitybio Inc. (IBRX) said on Monday that it has launched a mid-stage clinical study in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) with no need for chemotherapy.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell">said</a> that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab, and will not require any lymphodepleting chemotherapy unlike conventional CAR-T cell therapies.<h2 class="st-heading-2">Why The Trial?</h2>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva. Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.The new mid-stage study is designed to evaluate whether further stimulation of innate and adaptive immune responses may enhance the depth and durability of anti-tumor activity, Immunitybio said, while adding that the company is hopeful for Anktiva potentially augmenting the actions of the cell therapy and Rituximab.The study will enroll patients with indolent NHL, including Waldenström’s Macroglobulinemia, who are relapsed or are refractory after at least two prior lines of therapy. Treatment will be provided without chemotherapy.<h2 class="st-heading-2">Anktiva Troubles</h2>Last month, Immunitybio said that it recently met with the U.S. Food and Drug Administration to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.The company had submitted the application in 2025 but was rejected and is now looking to resubmit it with more information. The company then said that it would submit the additional information within 30 days, and that the added information does not need a new trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IBRX shares remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained about 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs

The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.

<ul class="summary-bullets"><li>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million.</li><li>For the current quarter (Q2), the company expects to report revenue of approximately $107 million to $108 million, marking a growth of approximately 16% percent year over year.</li><li>Twist also said that it expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.</li></ul>Shares of Twist Bioscience Corporation (TWST) jumped 8% on Monday after the company hiked its fiscal year 2026 revenue guidance on the heels of a first-quarter (Q1) earnings report that beat Wall Street estimates.<h2 class="st-heading-2">Upbeat Outlook</h2>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million, and exceeding an analyst estimate of $430.84 million, according to data from Fiscal AI. &nbsp;For the current quarter (Q2), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.twistbioscience.com/static-files/af6dbd56-d91e-429e-b337-a8e2675fc255">expects</a> to report revenue of approximately $107 million to $108 million, marking a growth of about 16% percent year over year at the midpoint, and exceeding an estimated $105.08 million.Twist also said that it expects to achieve adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) breakeven in the fourth-quarter of fiscal 2026.<h2 class="st-heading-2">Q1 Numbers</h2>For Q1, the company reported total revenue of $103.7 million, marking a growth of 17%, and above an expected $100.33 million, due to an increase in customers. The company said that it shipped products to about 2,538 customers in Q1 of fiscal 2026, versus approximately 2,376 in the same quarter of the previous fiscal year.Net loss for the quarter came in at $30.5 million, compared to $31.6 million in the corresponding quarter of fiscal 2025.The company also ended the quarter with $198 million in cash, cash equivalents, and short-term investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TWST stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A user applauded the earnings as “solid” progress for investors.<stembedurl>https://www.stocktwits.com/DBRGLong/message/643661292</stembedurl><a href="https://stocktwits.com/symbol/TWST">TWST stock</a> has dropped 16% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-bond-offering-funding-ai-cloud-infrastructure/cZbgYA1R4ki">ORCL Stock In Focus As Tech Giant Reportedly Launches Bond Offering To Cover Half Of 2026 Funding Needs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TWST Shares Rise 8% — What’s Driving The Rally?

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 

<ul class="summary-bullets"><li>The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.</li><li>Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA.</li></ul>Shares of Protalix BioTherapeutics, Inc. (PLX) closed 13% higher on Friday after it announced that a European Medicines Agency committee has recommended approval of a new dosing regimen for pegunigalsidase alfa, marketed as Elfabrio, in Fabry disease.The Committee for Medicinal Products for Human Use <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.protalix.com/news-releases/news-release-details/chiesi-global-rare-diseases-and-protalix-biotherapeutics-4">recommended</a> approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients. Currently approved dosing regimen requires patients to visit infusion centers every two weeks for treatment while the proposed new regimen would allow it to be stretched to every four weeks.<h2 class="st-heading-2">Turnaround</h2>The positive opinion follows CHMP’s re-examination of the company’s application for the additional dosing regimen. The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA. The agency is expected to announce a decision by March 2026.Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A enzyme, leading to harmful accumulation of fats in cells. Symptoms include severe neuropathic pain in hands/feet, skin lesions, decreased sweating, and organ damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PLX stock improved from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user appreciated that the company was persistent in getting a positive opinion. However, the stock should have rallied more on the news, they said.“But the $25 million is great news and hopefully should lessen the risk of capital raise for their gout trials. Finally, one decent obstacle out of the way,” they wrote.<stembedurl>https://www.stocktwits.com/BryGuy29/message/643515194</stembedurl><a href="https://stocktwits.com/symbol/PLX">PLX stock</a> has dropped about 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/peloton-reportedly-lays-off-11-percent-workforce/cmySvT7R4Sv">Peloton Reportedly Lays Off 11% Workforce Including Engineers In Cost-Cutting Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.

<ul class="summary-bullets"><li>Attorney General's petition for review challenges PHMSA’s attempt to evade state regulation through its orders to federalize the Las Flores Pipelines.</li><li>Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.&nbsp;</li><li>The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill.&nbsp;</li></ul>Sable Offshore shares plunged more than 14% on Friday after its two California pipeline restart came under scrutiny from a California Attorney General.&nbsp;California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.<h2 class="st-heading-2">Lawsuit Details</h2>Filed in the United States Court of Appeals for the Ninth Circuit, the Attorney General's petition for review challenges PHMSA’s alleged attempt to evade state regulation through its orders to federalize the Las Flores Pipelines, approve Sable Offshore’s restart plan, and issue Sable an emergency permit to restart oil transport through the pipelines.California Attorney General Rob Bonta, in a statement, said the administration broke the law by reclassifying the Las Flores pipelines last month as "interstate" even though they run between two California counties and are subject to state regulation.&nbsp;“In its latest unlawful power grab, the Trump Administration is illegally claiming exclusive federal authority over two of California's onshore pipelines. California has seen first-hand the devastating environmental and public health impacts of coastal oil spills — yet the Trump Administration will stop at nothing to evade state regulation which protects against these very disasters,” Bonta in a statement.&nbsp;<h2 class="st-heading-2">Sable’s Pipelines</h2>Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.&nbsp;“PHMSA has issued an emergency special permit for segments of the interstate Santa Ynez Pipeline System (specifically segments 324 and 325), approving the Company’s implementation of enhanced integrity management practices and specifying operational conditions,” it said in a statement.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around SOC trended in ‘bearish’ territory amid ‘extremely low’ message volume.&nbsp;Shares in the company have fallen 62% over the past 12 months.&nbsp; &nbsp;

A deserted oil factory in Maracaibo, Venezuela, pictured on December 27, 2019. (Photo by Humberto Matheus/NurPhoto via Getty Images)

Sable Offshore Plunged 14% Today – What Is The Feud With California State?

California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders of allowing Sable Offshore’s two pipelines to restart operations.

<ul class="summary-bullets"><li>The company said the property and equipment is located in Radersburg, Montana and was acquired for $4.75 million in cash.</li><li>The company said it has budgeted approximately $2 million in future capital expenditures to make specific equipment improvements to this facility.&nbsp;</li></ul>Shares of United States Antimony Corporation (UAMY) rallied on Friday led by optimism among retail traders who expect the stock price to double this year.&nbsp;The stock was up more than 7% at the time of writing and was among the top trending stocks on Stocktwits.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around UAMY trended in ‘extremely bullish’ territory amid ‘high’ message volume.One bullish user said that ‘sky’s the limit for the stock’.<stembedurl>https://stocktwits.com/jayrebs71/message/642708197</stembedurl>Another user predicted the stock to hit $20.<stembedurl>https://stocktwits.com/Milodino12/message/642705651</stembedurl>Shares in the company have rallied 514% over the past 12 months.&nbsp;<h2 class="st-heading-2">Recent News</h2>United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility. The property and equipment which is located in Radersburg, Montana, between Helena and Bozeman, Montana, is fully operational, and was acquired for $4.75 million in cash, it said in a statement.The company also said that it has budgeted approximately $2 million in future capital expenditures to make specific equipment improvements to this facility.&nbsp;The Radersburg Mill is a mineral processing facility equipped with both gravity and flotation circuits enabling the concentration of many minerals including stibnite, the primary antimony mineral. The facility has crushing and grinding circuits that reduce the ore to small particles in order to "liberate" target minerals such as gold, silver, copper, tungsten or stibnite amongst many others, the company said.&nbsp; &nbsp;

In this photo illustration, the United States Antimony (US Antimony) logo is seen displayed on a smartphone screen.

Why This Small-Cap Penny Stock Is Rallying Today – Traders Expect Stock Price To Double

United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility.

<ul class="summary-bullets"><li>BigBear.ai’s CEO Kevin McAleenan has told company shareholders that the firm is running low on available shares.</li><li>Proxy shareholder firms ISS and Glass Lewis have both recommended voting in favour of the proposal.</li><li>Company’s CFO Sean Ricker said earlier this month that the company was “97% of the way” to reaching the required votes.</li></ul>Shares of Bigbear.ai were under investors’ radar and the top trending stock on Stocktwits ahead of its shareholder vote deadline on the company's proposal to increase its authorized common stock.&nbsp;The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares. The shareholder vote deadline is till 11:59 PM ET on Wednesday. The approval will be decided at a reconvened special meeting on Thursday.&nbsp;BigBear.ai’s proposal to increase the authorized shares had failed to secure enough votes last month.&nbsp;<h2 class="st-heading-2">Why It Matters</h2>Authorized shares put a legal maximum limit of shares a company can issue. Increasing the limit of authorized shares helps a company make finance acquisitions and compensate its employees with stock.&nbsp;BigBear.ai’s CEO Kevin McAleenan has told company shareholders that the firm is running low on available shares and has urged shareholders to vote in favour of the amendment. He said that approval “would not result in the immediate issuance of new shares.”Proxy shareholder firms ISS and Glass Lewis have both recommended voting in favour of the proposal, he said in a letter to shareholders. “Having access to available authorized shares has allowed us over the years to make important acquisitions, fund product development and strengthen our balance sheet,” he added.&nbsp;The letter also said that additional shares would be available in the future to help fuel the company's growth as it looks to expand its AI capabilities, invest in its technology and Research and Development, invest in attracting and retaining top talent, and evaluating and acting on opportunistic financing and strategic initiatives.&nbsp;Company’s CFO Sean Ricker <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://bigbear.ai/blog/attention-shareholders-your-proxy-vote-questions-answered/?utm_source=ts2.tech">said</a> earlier this month that the company was “97% of the way” to reaching the required votes and added that “very few shares remain” under the current authorization.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BBAI trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares of the company have fallen 2.4% year-to-date.&nbsp; &nbsp;

The BigBear.ai Holdings Inc logo appears on a smartphone screen and as a background on a laptop screen in this photo illustration in Athens, Greece.

BigBear.ai Shares Tumble 8% Ahead Of Crucial Shareholder Vote Deadline On Increasing Authorized Shares

The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares.

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF